30
300298.SHE Sinocare Inc
- Market cap
- CNY 10.4B
- P/E
- 37.3x
- P/B
- 3.13x
- ROE
- 15.5%
- Dividend yield
- 1.30%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300298.SHE undervalued?
Graham number300298.SHE trades 128.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sinocare Inc fundamental analysis
No fundamental analysis for Sinocare Inc yet.
Sinocare Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sinocare Inc
Sinocare Inc. provides digital diabetes management products in the People's Republic of China. It offers blood and pressure products, multiparameter testing, and hospital and primary healthcare products; H102 Air, a hemoglobin monitoring system; and Safe AQ UA II, a uric acid monitoring system. The company also exports its products. Sinocare Inc. was founded in 2002 and is based in Changsha, the People's Republic of China.
Full company profileSinocare Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sinocare Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 796M | 1.03B | 1.55B | 1.78B | 2.02B | 2.36B | 3.95B | 4.06B | 4.44B | 4.66B | 5.12B |
| Gross Profit | 510M | 697M | 987M | 1.15B | 1.30B | 1.39B | 2.05B | 2.15B | 2.42B | 2.27B | 2.74B |
| Operating Income | 72.8M | 297M | 345M | 274M | 236M | 139M | 376M | 275M | 399M | 293M | 641M |
| EBITDA | 171M | 325M | 370M | 420M | 441M | 354M | 584M | 599M | 621M | 310M | 624M |
| Net Income | 115M | 258M | 310M | 251M | 187M | 108M | 447M | 284M | 326M | 92.6M | 495M |
| EPS | 0.24 | 0.53 | 0.56 | 0.45 | 0.34 | 0.19 | 0.80 | 0.51 | 0.59 | 0.17 | 0.89 |
| Balance Sheet | |||||||||||
| Total Assets | 1.47B | 1.66B | 3.00B | 3.28B | 3.90B | 4.15B | 4.62B | 5.93B | 6.10B | 5.96B | 6.21B |
| Total Liabilities | 196M | 273M | 377M | 633M | 1.15B | 1.36B | 1.47B | 2.46B | 2.33B | 2.52B | 2.70B |
| Shareholders' Equity | 1.28B | 1.39B | 2.62B | 2.65B | 2.73B | 2.79B | 3.12B | 3.08B | 3.36B | 3.11B | 3.20B |
| Cash & Short-term Investments | 216M | 323M | 663M | 566M | 1.14B | 932M | 844M | 816M | 955M | 779M | 679M |
| Total Debt | - | 14.9M | 2.64M | 162M | 554M | 655M | 524M | 982M | 597M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 203M | 244M | 319M | 523M | 505M | 480M | 474M | 735M | 631M | 605M | - |
| Capital Expenditure | 55.5M | 98.7M | 242M | 422M | 276M | 404M | 311M | 347M | 187M | 199M | 138M |
| Free Cash Flow | 148M | 145M | 76.9M | 101M | 229M | 76.2M | 163M | 389M | 445M | 406M | 484M |
| Ratios | |||||||||||
| ROE | 9.0% | 18.6% | 11.8% | 9.5% | 6.8% | 3.9% | 14.3% | 9.2% | 9.7% | 3.0% | 15.5% |
| ROA | 7.8% | 15.5% | 10.3% | 7.6% | 4.8% | 2.6% | 9.7% | 4.8% | 5.4% | 1.6% | 8.0% |
| Net Profit Margin | 14.5% | 25.0% | 20.0% | 14.1% | 9.3% | 4.6% | 11.3% | 7.0% | 7.3% | 2.0% | 9.7% |
| Debt to Equity | - | 0.01x | 0.00x | 0.06x | 0.20x | 0.24x | 0.17x | 0.32x | 0.18x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sinocare Inc dividends
- Dividend yield
- 1.30%
- Forward dividend
- -
- Payout ratio
- 145.8%
- Ex-dividend date
- Jun 13, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 135M | 0.24 | 145.8% |
| 2024 | CNY 132M | 0.24 | 40.5% |
| 2023 | CNY 111M | 0.20 | 39.2% |
| 2022 | CNY 112M | 0.20 | 25.0% |
| 2021 | CNY 113M | 0.20 | 105.1% |
| 2020 | CNY 168M | 0.30 | 89.8% |
| 2019 | CNY 170M | 0.30 | 67.7% |
| 2018 | CNY 142M | 0.25 | 45.8% |
| 2017 | CNY 122M | 0.25 | 47.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jul 16, 2018.
Who owns Sinocare Inc
- Insiders 53.84%
- Institutions 4.59%
- Public & others 41.57%
- Shares outstanding 557M
- Free float 247M
Sinocare Inc company profile
- Company name
- Sinocare Inc
- Ticker
- 300298.SHE
- ISIN
- CNE100001CJ0
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Mar 19, 2012
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 5,010
- Fiscal year end
- December
- Address
- No. 265 Guyuan Road, Changsha, China, 410205
- Phone
- 86 731 8993 5529
- Website
- sinocare.com
About Sinocare Inc
Sinocare Inc. provides digital diabetes management products in the People's Republic of China. It offers blood and pressure products, multiparameter testing, and hospital and primary healthcare products; H102 Air, a hemoglobin monitoring system; and Safe AQ UA II, a uric acid monitoring system. The company also exports its products. Sinocare Inc. was founded in 2002 and is based in Changsha, the People's Republic of China.
Sinocare Inc management
8- Ms. Xinyi LiVice Chairman & GM · born 1990
- Mr. Zhuzi HeChief Financial Officer · born 1974
- Ms. Jiyun ZhengDeputy GM & Board Secretary · born 1987
- Mr. Shi Min WangDeputy General Manager · born 1969
- Mr. Shao Bo HuangEmployee Representative Director · born 1984
- Mr. Peng XumingDeputy General Manager · born 1987
- Bo TanAccounting Supervisor
- Huiyu XuSecurities Affairs Representative